Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

26.02 +0.57 (+2.24%)
Streaming Delayed Price Updated: 9:49 AM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanobiotix S.A. - ADSs

< Previous 1 2 3 4 5 6 Next >
News headline image
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
News headline image
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
From Nanobiotix
Via Business Wire
News headline image
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX Provides First Quarter Operational and Financial Update
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
From NANOBIOTIX
Via Business Wire
News headline image
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
From NANOBIOTIX
Via Business Wire
News headline image
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
From NANOBOTIX
Via Business Wire
News headline image
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.